STOCK TITAN

ContraFect to Present at the 2020 Cantor Global Virtual Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

ContraFect Corporation (Nasdaq: CFRX) announced that CEO Roger J. Pomerantz will participate in a Fireside Chat at the 2020 Cantor Global Virtual Healthcare Conference on September 16, 2020, at 9:20 AM ET. The event will be streamed live and archived on the company's website. ContraFect specializes in developing direct lytic agents for antibiotic-resistant infections, including its lead candidate, exebacase, which is in a pivotal Phase 3 trial and has received Breakthrough Therapy designation from the FDA for treating MRSA bloodstream infections.

Positive
  • None.
Negative
  • None.

YONKERS, N.Y., Sept. 09, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that Roger J. Pomerantz, M.D., President, Chief Executive Officer and Chairman of ContraFect, will participate in a Fireside Chat at the 2020 Cantor Global Virtual Healthcare Conference on Wednesday, September 16, 2020, at 9:20am ET.

A live webcast of the presentation will be available on the Investors & Media section of the Company’s website at www.contrafect.com. The presentation will also be available as an archived webcast for a limited time. 

About ContraFect:

ContraFect is a biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our platform of DLAs, which include lysins and amurin peptides. Lysins are a new class of DLAs which are recombinantly produced antimicrobial proteins with a novel mechanism of action associated with the rapid killing of target bacteria, eradication of biofilms and synergy with conventional antibiotics. Amurin peptides are a novel class of DLAs which exhibit broad-spectrum activity against a wide range of antibiotic-resistant Gram-negative pathogens, including Pseudomonas aeruginosa (P. aeruginosa), Acinetobacter baumannii, and Enterobacter species. We believe that the properties of our lysins and amurin peptides will make them suitable for targeting antibiotic-resistant organisms, such as methicillin-resistant Staph aureus (MRSA) and P. aeruginosa, which can cause serious infections such as bacteremia, pneumonia and osteomyelitis. We have completed a Phase 2 clinical trial for the treatment of Staph aureus bacteremia, including endocarditis, with our lead lysin candidate, exebacase, which is the first lysin to enter clinical studies in the U.S. Exebacase, currently being studied in a pivotal Phase 3 clinical study, was granted Breakthrough Therapy designation by the FDA for the treatment of MRSA bloodstream infections (bacteremia), including right-sided endocarditis, when used in addition to standard-of-care anti-staphylococcal antibiotics in adult patients. 

Follow ContraFect on Twitter @ContraFectCorp and LinkedIn.

Forward-Looking Statements:

This press release contains, and our officers and representatives may make from time to time, “forward-looking statements” within the meaning of the U.S. federal securities laws. Forward-looking statements can be identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential,” “promise” or similar references to future periods. Examples of forward-looking statements in this release include, without limitation, statements regarding: ContraFect’s ability to discover and develop DLAs as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, whether ContraFect will address life-threatening infections using its DLA platform, whether lysins are a new class of DLAs which are recombinantly produced, antimicrobial proteins with a novel mechanism of action associated with the rapid killing of target bacteria, eradication of biofilms and synergy with conventional antibiotics, whether amurins are a novel class of DLAs which exhibit broad-spectrum activity against a wide range of antibiotic-resistant Gram-negative pathogens, and whether the properties of ContraFect’s lysins and amurins will make them suitable for targeting antibiotic-resistant organisms, such as MRSA and P. aeruginosa. Forward-looking statements are statements that are not historical facts, nor assurances of future performance. Instead, they are based on ContraFect’s current beliefs, expectations and assumptions regarding the future of its business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and changes in circumstances that are difficult to predict and many of which are beyond ContraFect’s control, including those detailed under the caption “Risk Factors” in ContraFect's filings with the Securities and Exchange Commission. Actual results may differ from those set forth in the forward-looking statements. Important factors that could cause actual results to differ include, among others, our ability to develop treatments for drug-resistant infectious diseases. Any forward-looking statement made by ContraFect in this press release is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, ContraFect expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investor Relations Contacts:

Michael Messinger
ContraFect Corporation
Tel: 914-207-2300
Email: mmessinger@contrafect.com

Carlo Tanzi, Ph.D.
Kendall Investor Relations
Tel: 617-914-0008
Email: ctanzi@kendallir.com


FAQ

What is ContraFect Corporation's focus area related to antibiotic resistance?

ContraFect Corporation specializes in discovering and developing direct lytic agents (DLAs) to treat life-threatening, antibiotic-resistant infections.

When will Roger J. Pomerantz participate in the 2020 Cantor Global Virtual Healthcare Conference?

Roger J. Pomerantz will participate in the conference on September 16, 2020, at 9:20 AM ET.

How can I watch the live webcast of the conference presentation?

The live webcast will be available in the Investors & Media section of ContraFect's website at www.contrafect.com.

What is the significance of exebacase in ContraFect's development pipeline?

Exebacase is ContraFect's lead lysin candidate, currently in a pivotal Phase 3 study and granted Breakthrough Therapy designation for treating MRSA bloodstream infections.

What is the estimated global impact of antimicrobial-resistant infections each year?

An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections.

ContraFect Corporation

NASDAQ:CFRX

CFRX Rankings

CFRX Latest News

CFRX Stock Data

535.24k
10.69M
0.65%
6.13%
2.16%
Biotechnology
Healthcare
Link
United States
Yonkers